Intermediate fibrosis staging in hepatitis C: a problem not overcome by optimal samples or pathologists’ expertise
Journal Title: Annals of Hepatology - Year 2015, Vol 14, Issue 5
Abstract
Background and aims. The prediction of intermediate stage of fibrosis in chronic hepatitis C represents a prognostic factor for disease progression. Studies evaluating biopsy performance in intermediate stage considering current patterns of liver samples and pathologists’ variability are scarce. We aimed to evaluate the effect of optimal liver specimens (≥ 20 mm and/or ≥ 11 portal tracts) and pathologists’ expertise on agreement for intermediate stage of fibrosis in chronic hepatitis C. Material and methods. Guided biopsies with large TruCut needle were initially scored by four pathologists with different expertise in liver disease and posteriorly reviewed by a reference hepatopathologist to evaluate fibrosis agreement. Results. Of the 255 biopsies initially selected, 240 met the criteria of an optimal fragment (mean length 24 ± 5 mm; 16 ± 6 portal tracts) and were considered for analysis. The overall agreement among all fibrosis stages was 77% (κ = 0.66); intraobserver and interobserver agreement was, respectively, 97% (k = 0.96) and 73% (κ = 0.60). Excluded samples (< 20 mm and < 11 portal tracts) presented a lower agreement (40%; κ = 0.24). Stratifying fibrosis stages, an interobserver agreement of 42% was found in intermediate stage (F2), ranging from 0 to 56% according to pathologists’ expertise, compared to 97% in mild (F0-F1) and 72% in advanced fibrosis (≥ F3) (p < 0.001). Of the 23% misclassified cases, fibrosis understaging occurred in 82% of specimens, predominantly in F2, even when evaluated by a hepatopathologist. Conclusions. Liver biopsy presents intrinsic limitations to assess intermediate stage of fibrosis not overcome by optimal samples and experienced pathologists’ analysis, and should not be considered the gold standard method to evaluate intermediate fibrosis in chronic hepatitis C.
Authors and Affiliations
Maria C. Chindamo, Vera L. Nunes-Pannain, João M. Araújo-Neto, Henrique S. Moraes-Coelho, Ronir R. Luiz, Cristiane A. Villela-Nogueira, Renata M. Perez
Keywords
Related Articles
- EP ID EP78490
- DOI -
- Views 111
- Downloads 0
Takayasu arteritis associated with hepatic sinusoidal dilatation
Assessment of hepatic fibrosis and necroinflammation among inactive HBsAg carriers in Egypt
Introduction. The inactive hepatitis B surface antigen (HBsAg) carrier state is usually characterized by minimal or absent liver pathology. However, in developing countries, owing to the very early age of infection with...
Hepatitis C virus infection in patients and family members attending two primary care clinics in Puebla, Mexico
Background. Approximately 180 million persons (~2.8%) globally are estimated to be infected by hepatitis C virus (HCV). HCV prevalence in Mexico has been estimated to be between 1.2 and 1.4%. The aim of present work was...
A Summary of The 6th International Conference on Coagulation in Liver Disease: Discussion, Debate, Deliberations
IN MEMORIAM-Professor Andrew Burroughs